Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 145

1.

A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease.

Bianchi S, Bigazzi R, Caiazza A, Campese VM.

Am J Kidney Dis. 2003 Mar;41(3):565-70. Erratum in: Am J Kidney Dis. 2004 Jan;43(1):193.

PMID:
12612979
2.

The acute effect of atorvastatin on proteinuria in patients with chronic glomerulonephritis.

Ozsoy RC, Koopman MG, Kastelein JJ, Arisz L.

Clin Nephrol. 2005 Apr;63(4):245-9.

PMID:
15847250
3.

Intensive versus conventional therapy to slow the progression of idiopathic glomerular diseases.

Bianchi S, Bigazzi R, Campese VM.

Am J Kidney Dis. 2010 Apr;55(4):671-81. doi: 10.1053/j.ajkd.2009.11.006. Epub 2010 Jan 25.

PMID:
20097461
4.

Antagonists of aldosterone and proteinuria in patients with CKD: an uncontrolled pilot study.

Bianchi S, Bigazzi R, Campese VM.

Am J Kidney Dis. 2005 Jul;46(1):45-51.

PMID:
15983956
5.

Effects of atorvastatin on inflammatory and fibrinolytic parameters in patients with chronic kidney disease.

Goicoechea M, de Vinuesa SG, Lahera V, Cachofeiro V, Gómez-Campderá F, Vega A, Abad S, Luño J.

J Am Soc Nephrol. 2006 Dec;17(12 Suppl 3):S231-5.

6.
7.

The effect of atorvastatin on serum lipids, lipoprotein(a) and plasma fibrinogen levels in primary dyslipidaemia--a pilot study involving serial sampling.

Goudevenos JA, Bairaktari ET, Chatzidimou KG, Milionis HJ, Mikhailidis DP, Elisaf MS.

Curr Med Res Opin. 2001;16(4):269-75.

PMID:
11268711
8.
9.

Role of hyperlipidemia in progressive renal disease: focus on diabetic nephropathy.

Jandeleit-Dahm K, Cao Z, Cox AJ, Kelly DJ, Gilbert RE, Cooper ME.

Kidney Int Suppl. 1999 Jul;71:S31-6. Review.

PMID:
10412733
10.

Beneficial effects of atorvastatin on sd LDL and LDL phenotype B in statin-naive patients and patients previously treated with simvastatin or pravastatin.

Baldassarre S, Scruel O, Deckelbaum RJ, Dupont IE, Ducobu J, Carpentier YA.

Int J Cardiol. 2005 Oct 10;104(3):338-45.

PMID:
16186066
11.

Effect of low doses of atorvastatin on adiponectin, glucose homeostasis, and clinical inflammatory markers in kidney transplant recipients.

Bayés B, Granada ML, Lauzurica R, Pastor MC, Navarro M, Bonet J, Llopis MA, Romero R.

Transplant Proc. 2005 Nov;37(9):3808-12.

PMID:
16386546
12.
13.

Antihypertensive therapy and the benefits of atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial: lipid-lowering arm extension.

Sever PS, Poulter NR, Dahlof B, Wedel H; ASCOT Investigators.

J Hypertens. 2009 May;27(5):947-54. doi: 10.1097/HJH.0b013e328326cb1a.

PMID:
19318984
14.

Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.

Jones PH, Hunninghake DB, Ferdinand KC, Stein EA, Gold A, Caplan RJ, Blasetto JW; Statin Therapies for Elevated Lipid Levels Compared Across Doses to Rosuvastatin Study Group.

Clin Ther. 2004 Sep;26(9):1388-99. Erratum in: Clin Ther. 2005 Jan;27(1):142.

PMID:
15531001
15.

Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD.

Koren MJ, Davidson MH, Wilson DJ, Fayyad RS, Zuckerman A, Reed DP; ALLIANCE Investigators.

Am J Kidney Dis. 2009 May;53(5):741-50. doi: 10.1053/j.ajkd.2008.11.025. Epub 2009 Feb 11.

PMID:
19216014
16.

Comparison of rosuvastatin versus atorvastatin in Hispanic-Americans with hypercholesterolemia (from the STARSHIP trial).

Lloret R, Ycas J, Stein M, Haffner S; STARSHIP Study Group.

Am J Cardiol. 2006 Sep 15;98(6):768-73. Epub 2006 Jul 28.

PMID:
16950182
17.

Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease.

Kunz R, Friedrich C, Wolbers M, Mann JF.

Ann Intern Med. 2008 Jan 1;148(1):30-48. Epub 2007 Nov 5.

PMID:
17984482
18.

Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin.

Stein E, Stender S, Mata P, Sager P, Ponsonnet D, Melani L, Lipka L, Suresh R, Maccubbin D, Veltri E; Ezetimibe Study Group.

Am Heart J. 2004 Sep;148(3):447-55.

PMID:
15389231
19.

Comparison of the efficacy and tolerability of pitavastatin and atorvastatin: an 8-week, multicenter, randomized, open-label, dose-titration study in Korean patients with hypercholesterolemia.

Lee SH, Chung N, Kwan J, Kim DI, Kim WH, Kim CJ, Kim HS, Park SH, Seo HS, Shin DG, Shin YW, Shim WJ, Ahn TH, Ho Yun K, Yoon MH, Cha KS, Choi SW, Han SW, Hyon MS.

Clin Ther. 2007 Nov;29(11):2365-73.

PMID:
18158077
20.

Effect of low doses of atorvastatin on the urinary peptide profile of kidney transplant patients.

Pérez V, Navarro-Muñoz M, Bayés B, Lauzurica R, Pastor MC, Troya M, Bonet J, Ibernón M, Navarro M, Serra A, Núñez A, Romero R.

Transplant Proc. 2009 Jul-Aug;41(6):2111-4. doi: 10.1016/j.transproceed.2009.06.170.

PMID:
19715847
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk